Previous 10 |
home / stock / ngen:cc / ngen:cc news
30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at Pfizer Experience on 16 development stage products, 15 commercial stage products and numerous pre-clinical assets, in both start-up and large pharmaceutical companies Vancouver, British Columb...
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the C...
Human subjects now being enrolled in the second cohort of multiple ascending dose portion of the study NVG-291 dose administered in the first cohort is already above the highest corresponding dose found to be efficacious in animal models and is substantially higher than the lower effective d...
Engages Apaton Finance to Provide Investor Relations Services in Europe Vancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutio...
The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal models Approval moves NervGen one step closer to Phase 1b/2 efficacy studies in Alzheimer's disease, multiple sclerosis and spinal cord injury p...
News, Short Squeeze, Breakout and More Instantly...
Nervgen Pharma Corp. Company Name:
NGEN:CC Stock Symbol:
TSXVC Market:
Nervgen Pharma Corp. Website:
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company's mission to advance NVG-291 after the completion of the ongoing Phase 1b/2a study Vancouver, British Columbia--(Newsfile Corp. - July 22...
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...